NCT05675605View on ClinicalTrials.gov

A Study of TY-1091 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

December 1, 2025

Conditions
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid CancerNeoplasms
Interventions
DRUG

TY-1091

TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg

Trial Locations (1)

130000

RECRUITING

Jinlin Province Cancer Hosipital, Changchun

All Listed Sponsors
lead

TYK Medicines, Inc

INDUSTRY